{
  "id": 7042139,
  "title": "Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer",
  "url": "https://urgent.news/2026/09/13/trial-shows-risvutatug-rezetecan-significantly-improves-overall",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-13T01:50:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-trial-risvutatug-rezetecan-significantly-survival.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. The findings were presented today at the IASLC 2026 World Conference on…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Trial supports MRI surveillance over preventive brain radiation in small-cell lung cancer",
        "url": "https://urgent.news/2026/09/13/trial-supports-mri-surveillance-over-preventive-brain-radiation-in",
        "published": "2026-09-13T01:50:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}